TIMP1 and prostate cancer: We found that TIMP-1 enhances ERK1/2 activity of serum starved prostate CAFs but not prostate cancer cells (Figure 8B-C), suggesting that the in vivo effects of TIMP-1 on prostate cancer cells might be exerted through affecting prostate CAFs indirectly (Figure 9).